— Only one person developed HIV infection in year-long extensions of two PURPOSE trials
August 1, 2026
• 3 min read
Only one person has developed a new HIV infection during a year-long extension of the landmark PURPOSE 1 and PURPOSE 2 trials testing twice-yearly injectable lenacapavir (Yeztugo) for pre-exposure prophylaxis (PrEP), according to twin open-label extensions.
There were no new HIV cases in the PURPOSE 1 52-week open-label extension among adolescent girls and young women in South Africa and Uganda. That extension included 2,136 patients who remained on lenacapavir after the trial's randomized blinded phase ended, and 2,496 patients who switched at the extension's start to lenacapavir from either daily oral emtricitabine and tenofovir alafenamide (Descovy) or emtricitabine and tenofovir disoproxil fumarate (Truvada).
